Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (BR112015001028) antagonistas de receptor 5-ht3

Office : Brazil
Application Number: 112015001028 Application Date: 16.07.2013
Publication Number: 112015001028 Publication Date: 27.06.2017
Publication Kind : A2
Prior PCT appl.: Application Number:PCTUS2013050746 ; Publication Number:WO2014014951 Click to see the data
IPC:
C 07
C 07
C 07
C 07
C 07
C 07
C 07
C 07
[IPC code unknown for ERROR IPC Code incorrect: invalid group (0=>9999)!][IPC code unknown for ERROR IPC Code incorrect: invalid group (0=>9999)!][IPC code unknown for ERROR IPC Code incorrect: invalid group (0=>9999)!][IPC code unknown for ERROR IPC Code incorrect: invalid group (0=>9999)!][IPC code unknown for ERROR IPC Code incorrect: invalid group (0=>9999)!][IPC code unknown for ERROR IPC Code incorrect: invalid group (0=>9999)!][IPC code unknown for ERROR IPC Code incorrect: invalid group (0=>9999)!][IPC code unknown for ERROR IPC Code incorrect: invalid group (0=>9999)!]
Applicants: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventors: HOLGER MONENSCHEIN
HOLLY REICHARD
HUIKAI SUN
MARIA HOPKINS
SHOTA KIKUCHI
STEPHEN HITCHCOCK
TODD MACKLIN
Agents: DANNEMANN, SIEMSEN, BIGLER & IPANEMA MOREIRA
Priority Data: 61/672,709 17.07.2012 US
61/708,521 01.10.2012 US
Title: (PT) antagonistas de receptor 5-ht3
Abstract:
(PT) abstract the present invention provides 5-ht3 receptor antagonists of formula (i):which are useful for the treatment of diseases treatable by inhibition of 5-ht3 receptor such as emesis, pain, drug addiction, neurodegenerative and psychiatric disorders, and gi disorders. also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.tradução do resumoresumo"antagonistas de receptor 5-ht3". a presente invenção provê antagonistas de receptor 5-ht3 da fórmula (i): os quais são úteis para o tratamento de doenças tratáveis por inibição de receptor 5-ht3, tais como emese, dor, toxicodependência, distúrbios neurodegenerativos e psiquiátricos e distúrbios gi. também são providas composições farmacêuticas contendo tais compostos e processos para preparar tais compostos.1/1
Also published as:
CA2879115IL236702DOP2015000009EP2875011EA201590228SG11201500302U
CN104768943JP2015522618NZ704814AU2013290375ID2016/04647MYPI 2015000110
PH1/2015/500085VN42301IN957/DELNP/2015ES2659758EP3312169TH180869
TN2015000018WO/2014/014951